Format

Send to

Choose Destination
Ann Oncol. 2014 Oct;25(10):2086-91. doi: 10.1093/annonc/mdu266. Epub 2014 Jul 23.

On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.

Author information

1
Department of Dermatology and Skin Cancers, UMR911 CRO2 caroline.gaudy@ap-hm.fr.
2
Department of Stereotaxic and Functional Neurosurgery, Gammaknife Unit, Inserm U751.
3
Department of Public Health, Aix-Marseille University, APHM, Marseille, France.
4
Department of Dermatology and Skin Cancers, UMR911 CRO2.

Abstract

BACKGROUND:

Both Gamma-Knife radiosurgery (GKRS) and BRAF inhibitors (BRAF-I) have been shown to be useful in melanoma patients with brain metastases (BMs), thus suggesting that it could be interesting to combine their respective advantages. However, cases of radiosensitization following conventional radiation therapy in BRAF-I treated patients have raised serious concerns about the real feasibility and risk/benefit ratio of this combination.

PATIENTS AND METHODS:

Review by two independent observers of brain magnetic resonance imaging (MRI) follow-up pictures, and volume and edema quantifications, and survival assessment in all patients who had been treated by GKRS and BRAF-I at a single institution.

RESULTS:

Among 53 GKRS carried out in 30 patients who ever received BRAF-I and GKRS, 33 GKRS were carried out in 24 patients while under BRAF-I treatment, from which only 4 with an interruption of BRAF-I. The 20 other GKRS were carried out in 15 patients (including 9 of the 24) before initiation of BRAF-I treatment. No case of radiation-induced necrosis and no scalp radiation dermatitis occurred. A >20% increase in volume was observed in 35 of the 263 BM treated by GKRS (13.3%), but only 3 clear-cut edemas and 3 hemorrhages were detected within 2 months after GKRS, and 4 edemas and 7 hemorrhages later. Neither the MRI features nor the incidence of the volume changes, hemorrhage and edema were deemed unexpected for melanoma BM treated by GKRS. Median survival from first GKRS under BRAF-I and first dose of BRAF-I were 24.8 and 48.8 weeks, respectively.

CONCLUSION:

This series does not show immediate radiotoxicity nor radiation recall, in melanoma patients with BRAF-I whose BMs are treated by GKRS. Interrupting BRAF-I for stereotactic radiosurgery (SRS) of BM seems useless, although it is still advised for other radiation therapies. The potential benefit of combining SRS and BRAF-I can be safely tested.

KEYWORDS:

BRAF inhibitors; Gamma-Knife radiosurgery; brain metastasis; metastatic melanoma; radiosensitization

PMID:
25057167
DOI:
10.1093/annonc/mdu266
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center